You are using an outdated browser. Please upgrade your browser to improve your experience.

tivozanib

Ligand Summary
Ligand Structure
Rendered image for the query structure
Description
Tivozanib is an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI). It is a potent, selective and long half-life inhibitor of all three VEGF receptors and is designed to optimize VEGF blockade while minimizing off-target toxicities, potentially resulting in improved efficacy and minimal dose modifications. Tivozanib is indicated as first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naive following disease progression after one prior treatment with cytokine therapy for advanced RCC.
Synonyms & Links
Guide to Pharmacology: 6058
DrugCentral: 5258
LyCHI:  G8GCH7A2RSAN


loading...
Target Activities